We speak to medical oncologist Narjust Duma, from the University of Wisconsin in the USA, about COVID-19 vaccination in people with cancer, discussing issues such as vaccine timing, side-effects, and key unanswered research questions.

In this Medicine Matters oncology podcast, we speak to Gary Lyman (Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, USA) about the impact of the COVID-19 outbreak on the conduct of cancer clinical trials.

Find more on Medicine Matters oncology

Co-project leader Lennard Lee talks about the inception and development of the initiative that will provide insight into the impact of COVID-19 on people with cancer and facilitate shared learning that will benefit patient care.

Find more on Medicine Matters oncology

Gilberto Lopes (Sylvester Comprehensive Cancer Center at the University of Miami, Florida, USA), a steering committee member of CCC19, tells us about the registry collating data on cancer patients with comorbid COVID-19 to provide an evidence base for future decision-making.

Find more on Medicine Matters oncology

Image credit: © koto_feja/Getty Images/iStock

Thoracic oncology nurse practitioner Beth Sandy explains how the coronavirus pandemic is affecting cancer patient care and how strategies such as telemedicine are coming into their own.

Find more on Medicine Matters oncology

Image credit: Coronavirus illustration © dottedyeti/stock.adobe.com

Genitourinary oncologists Cora Sternberg (Weill Cornell Medicine, New York, USA) and Axel Merseburger (University Hospital Schleswig-Holstein, Lübeck, Germany) share their experience of managing cancer patients during the COVID-19 pandemic, comparing perspectives from a US and German stand point.

Find more on Medicine Matters oncology

Gilberto Lopes discusses the impact of the COVID-19 pandemic on the management of patients with lung cancer and outlines the measures being implemented to minimize the risk for patients.

Find more on Medicine Matters oncology

Colin Lindsay discusses the trial results for AMG 510 – a novel inhibitor targeting the KRAS G12C mutation –  in patients with locally advanced or metastatic non-small-cell lung cancer.

Find more on Medicine Matters oncology

More from WCLC 2019